Emergent BioSolutions Inc. (NYSE:EBS) Shares Sold by BNP Paribas Financial Markets

BNP Paribas Financial Markets lessened its holdings in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 65.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,470 shares of the biopharmaceutical company's stock after selling 58,544 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.06% of Emergent BioSolutions worth $263,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. CWM LLC lifted its holdings in shares of Emergent BioSolutions by 32,706.7% in the 2nd quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 4,906 shares during the last quarter. Meeder Asset Management Inc. bought a new stake in Emergent BioSolutions in the second quarter valued at $41,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of Emergent BioSolutions by 22.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 23,943 shares of the biopharmaceutical company's stock valued at $61,000 after acquiring an additional 4,409 shares during the period. Verus Capital Partners LLC bought a new position in shares of Emergent BioSolutions during the second quarter worth about $68,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Emergent BioSolutions in the 2nd quarter worth about $93,000. Institutional investors own 78.40% of the company's stock.

Analyst Ratings Changes

Several research analysts have commented on the stock. StockNews.com upgraded shares of Emergent BioSolutions from a "hold" rating to a "buy" rating in a research report on Thursday, December 12th. Rodman & Renshaw reissued a "buy" rating and issued a $16.00 price objective on shares of Emergent BioSolutions in a report on Friday, September 13th. Finally, Benchmark lifted their target price on Emergent BioSolutions from $8.00 to $12.00 and gave the company a "buy" rating in a research note on Thursday, November 7th.

Emergent BioSolutions Price Performance

Emergent BioSolutions stock traded down $0.09 during trading hours on Tuesday, hitting $8.78. 1,173,307 shares of the company traded hands, compared to its average volume of 3,171,290. The firm's 50-day simple moving average is $9.35 and its two-hundred day simple moving average is $8.75. The firm has a market cap of $475.74 million, a P/E ratio of -2.11 and a beta of 1.59. Emergent BioSolutions Inc. has a 1-year low of $1.42 and a 1-year high of $15.10. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.